

UNDERTAKING

TO: Autorité des marchés financiers

FROM: NervGen Pharma Corp. (the “**Company**”)

RE: Short form base shelf prospectus filed on August 12, 2022 (the “**Prospectus**”) relating to the issue and sale from time to time of common shares, debt securities, subscription receipts, warrants and units (collectively, the “**Securities**”)

In connection with the filing by the Company of the Prospectus, the Company hereby undertakes not to distribute Securities in Canada by way of an “at-the-market distribution” (as contemplated in Part 9 of National Instrument 44-102) (“**ATM**”) under the Prospectus unless the Company has filed an amendment to the Prospectus adding Québec as a jurisdiction in which the Securities will be distributed or otherwise obtained exemptive relief therefrom.

DATED as of August 12, 2022.

NERVGEN PHARMA CORP.

By: (Signed) “William Adams”
Name: William Adams
Title: Chief Financial Officer